NASDAQ · SPRO
Spero Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SPRO: Nov 12, 2026
Spero Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.13.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Dec 2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · MarketBeat · The Motley Fool · RTTNews- Fintel · Oct 28, 10:26 PM EDTCantor Fitzgerald Initiates Coverage of Spero Therapeutics at OverweightFintel reports that on October 28, 2026, Cantor Fitzgerald initiated coverage of Spero Therapeutics (NASDAQGS:SPRO) (DB:2HA) with a Overweight recommendation.Spero Therapeutics, Inc., based in the United States, operates within the biopharmaceutical sector, focusing primarily on
- Fintel · Oct 27, 11:38 PM EDTSpero Therapeutics, Inc. Announces Retirement of Chief Operating Officer Timothy KeutzerSpero Therapeutics, Inc. announced that Timothy Keutzer, the Company’s Chief Operating Officer, will retire from the Company effective as of December 31, 2026.In connection with his retirement, the Company expects to enter into a consulting arrangement with Mr. Keutzer on o
- MarketBeat · Oct 21, 2:02 AM EDTSpero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related DiseaseSpero Therapeutics (NASDAQ:SPRO) plans to initiate a Phase II trial of its lead immunology candidate, SP001, in immunoglobulin G4-related disease, or IgG4-RD, in the second quarter of 2027, Chief Executive Officer Esther Rajavelu said during a company presentation. SP001 is a th
- Fintel · Oct 1, 8:06 PM EDTSpero Therapeutics Consensus Price Target Raised 25% to $5.10The average one-year price target for Spero Therapeutics (NASDAQGS:SPRO) (DB:2HA) has been revised to $5.10 / share. This is an increase of 25.00% from the prior estimate of $4.08 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and d
- The Motley Fool · Aug 19, 5:28 PM EDTSpero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 12, 10:04 PM EDTSpero Therapeutics Q2 Earnings Call HighlightsSpero Therapeutics (NASDAQ:SPRO) used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-rel
- RTTNews · Jul 27, 9:02 AM EDTSpero Therapeutics Names Debra Jeske Zack As Chief Medical Officer(RTTNews) – Spero Therapeutics, Inc. (SPRO), a clinical-stage biopharmaceutical company, on Monday said it has appointed Debra Jeske Zack as Chief Medical Officer.
- RTTNews · Jul 14, 6:38 AM EDTInnovent Grants Spero Ex-China Rights To Anti-CD40L Antibody IBI355 In Up To $1.1 Bln Deal(RTTNews) – Innovent Biologics, Inc (IVBXF) said on Tuesday it entered into an exclusive licensing agreement with Spero Therapeutics, Inc. (SPRO) for IBI355, a third-generation Fc-silent anti-CD40L antibody being developed for autoimmune diseases.
- RTTNews · Jul 14, 6:38 AM EDTSpero Announces Royalty Financing Deal With Affiliates Of Healthcare Royalty(RTTNews) – Spero Therapeutics (SPRO) announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, or HCRx, a royalty acquisition company that is majority owned by KKR & Co. Inc. (KKR). The proceeds will primarily be used
- RTTNews · Jul 10, 5:02 AM EDTAvacta Appoints Patrick Vink As Deputy Chairman & Senior Independent Director To Its Board(RTTNews) – Avacta Group Plc (AVCT.L), a biopharmaceutical company developing pre|CISION oncology technology, announced the appointment of Patrick Vink as Non-Executive Deputy Chairman and Senior Independent Director to its Board of Directors.
- RTTNews · Jun 19, 5:09 AM EDTWeekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera(RTTNews) – This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts.
- Zacks · Jun 18, 8:57 AM EDTGSK's Utebzi Wins FDA Nod for Complicated Urinary Tract InfectionsGSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Spero Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.